Piper Jaffray analyst, Edward Tenthoff, reiterated his Overweight rating on shares of CRISPR Therapeutics (NASDAQ: CRSP) after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE